drugset
drugset / Trial / NCT04233593

Neuroimmune Response to Lipopolysaccharide

NCT04233593 ↗

Phase 1 Completed 27 enrolled Yale University
Non-randomizedSingle-groupOpen-labelBasic science

Summary

In this study, healthy adult volunteers will undergo two positron emission tomography (PET) scans using the radiotracer \[11C\]PBR28 which binds to the 18kDa translocator protein (TSPO). Approximately 3 hours prior to the second \[11C\]PBR28 PET scan, lipopolysaccharide (LPS; endotoxin) will be administered to evoke a robust neuroimmune response. Subjects will also undergo behavioral and cognitive testing. Vital signs, subjective response, and peripheral cytokine levels will be assayed periodically throughout the experimental session. Specific aims: Quantify the magnitude of neuroimmune response after a classical immune stimulus. Secondary aims: Quantify changes in cognitive function after a classical immune stimulus. Hypothesis: Individuals will exhibit a robust whole-brain neuroimmune response and impaired cognitive function after LPS.

Timeline

Start
2014-03-25
Primary completion
2021-08-17
Completion
2021-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Lipopolysaccharide Other / unclassified 1 unknown Intravenous

Indications

No indication recorded.